T1N0M0肺腺癌淋巴结清扫指南依从性与生存关联
结果显示,仅在高级别或无贴壁型组中,遵循3+1或6站标准清扫与小幅绝对生存获益相关,而贴壁无高级别型组无显著关联。
要点
- 高级别或无贴壁型肺腺癌遵循淋巴结清扫指南与小幅绝对生存获益相关。
- 贴壁无高级别型肺腺癌中指南依从性清扫与生存无显著关联。
- 研究为观察性设计,结果需前瞻性验证,不能解释为因果关系。
核心结论
- 在高级别或无贴壁型肺腺癌患者中,指南依从性淋巴结清扫与小幅绝对生存获益相关。
- 在贴壁无高级别型肺腺癌患者中,未观察到指南依从性清扫与生存的关联。
- 这些观察性发现需前瞻性验证,不应解释为因果。
研究设计与样本
- 暴露为淋巴结清扫是否遵循3+1标准(3个N2站加1个N1站)或6站标准(隆突下加2个其他N2站和3个N1站)。
- 主要结局为总生存。
主要发现
- 在贴壁无高级别型组中,3+1标准依从性与生存无关联(HR 0.81,95%CI 0.57-1.15),6站标准亦无关联(HR 0.54,95%CI 0.26-1.13)。
- 在高级别或无贴壁型组中,3+1标准依从性与生存相关(HR 0.81,95%CI 0.69-0.95;3年绝对风险差1.2%,95%CI 0.2%-2.2%;E值1.78)。
- 在高级别或无贴壁型组中,6站标准依从性与生存相关(HR 0.61,95%CI 0.45-0.83;3年绝对风险差1.0%,95%CI 0.1%-1.9%;E值2.67)。
关键数值与推荐
- 指南依从性清扫定义为遵循3+1标准(3个N2站加1个N1站)或6站标准(隆突下加2个其他N2站和3个N1站)。
- 组织学模式分组:贴壁无高级别型 vs 高级别或无贴壁型。
临床怎么用
- 对于高级别或无贴壁型肺腺癌患者,遵循指南进行淋巴结清扫可能带来小幅绝对生存获益。
- 对于贴壁无高级别型肺腺癌患者,指南依从性淋巴结清扫未显示生存获益,提示可个体化决策。
- 研究结果不能作为因果证据,临床决策需结合前瞻性验证。
局限性
- 为观察性队列研究,存在残余混杂可能。
- 作者指出结果需前瞻性验证,不应解释为因果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lymph node dissection for early-stage lung adenocarcinoma is controversial. Histologic pattern subtyping reveals heterogeneity of lung adenocarcinoma, yet its association with lymph node involvement and dissection is understudied. OBJECTIVE: To assess the association between guideline-adherent lymph node dissection, histologic pattern subtyping, and overall survival in patients with clinical T1N0M0 lung adenocarcinoma. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study used data from the National Cancer Center LungReal database, a multicenter, electronic health records-based database for patients undergoing surgery for lung cancer, from January 2014 to December 2021, with the last follow-up in December 2022. Patients were categorized based on histologic pattern of adenocarcinoma into 2 groups: lepidic without high-grade pattern, and high-grade or no lepidic pattern. The data analysis was performed from April to November 2025. EXPOSURE: Lymph node dissection adherence or nonadherence with the 3 + 1 standard (3 N2 plus 1 N1 station) and the 6-station standard (the subcarinal plus 2 other N2 stations and 3 N1 stations). MAIN OUTCOME AND MEASURE: Overall survival. RESULTS: Of 35 265 patients screened, 27 191 participants (mean [SD] age, 58.3 [11.7] years; 16 280 female [59.9%] and 10 911 male [40.1%] individuals) from 19 centers were included; among them, 15 593 (57.3%) received lymph node dissection adherent with the 3 + 1 standard and 4023 (14.8%) with the 6-station standard. Among the group of 13 369 patients (49.2%) with adenocarcinoma of lepidic without high-grade pattern, no association was observed between survival and adherence with the 3 + 1 standard (hazard ratio [HR], 0.81; 95% CI, 0.57-1.15) or the 6-station standard (HR, 0.54; 95% CI, 0.26-1.13). Whereas, among the group of 13 822 patients (50.8%) with adenocarcinoma of high-grade or no lepidic pattern, adherence with the 3 + 1 standard (HR, 0.81; 95% CI, 0.69-0.95; absolute risk difference at 3-year, 1.2%; 95% CI, 0.2%-2.2%; E-value, 1.78) or the 6-station standard (HR, 0.61; 95% CI, 0.45-0.83; absolute risk difference at 3 years, 1.0%; 95% CI, 0.1%-1.9%; E-value, 2.67) was associated with a significant but small absolute survival benefit. CONCLUSION AND RELEVANCE: In this cohort study, guideline-adherent nodal dissection was associated with small absolute survival benefit for patients with adenocarcinoma of high-grade or no lepidic pattern, but not for those with lepidic without high-grade pattern. These observational findings warrant prospective validation and should not be interpreted as causal.
引用
- Li R, Wang P, Zhang H, et al. Lymph Node Dissection Guideline Adherence and Survival in Patients With T1N0M0 Lung Adenocarcinoma. JAMA Oncol. 2026. PMID: 41538156. doi:10.1001/jamaoncol.2025.5924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。